title: A new drug delivery system inhibits uveitis in an animal model after cataract surgery.
abstract: Cataract surgery is a common ocular surgical procedure consisting in the implantation of an artificial intraocular lens (IOL) to replace the ageing, dystrophic or damaged natural one. The management of postoperative ocular inflammation is a major challenge especially in the context of pre-existing uveitis. The association of the implanted IOL with a drug delivery system (DDS) allows the prolonged intraocular release of anti-inflammatory agents after surgery. Thus IOL-DDS represents an "all in one" strategy that simultaneously addresses both cataract and inflammation issues. Polymeric DDS loaded with two model anti-inflammatory drugs (triamcinolone acetonide (TA) and cyclosporine A (CsA)) were manufactured in a novel way and tested regarding their efficiency for the management of intraocular inflammation during the 3 months following surgery. The study involved an experimentally induced uveitis in rabbits. Experimental results showed that medicated DDS efficiently reduced ocular inflammation (decrease of protein concentration in aqueous humour, inflammatory cells in aqueous humour and clinical score). Additionally, more than 60% of the loading dose remained in the DDS at the end of the experiment, suggesting that the system could potentially cover longer inflammatory episodes. Thus, IOL-DDS were demonstrated to inhibit intraocular inflammation for at least 3 months after cataract surgery, representing a potential novel approach to cataract surgery in eyes with pre-existing uveitis.
authors.affiliation: Jules Gonin Eye Hospital, Lausanne University, 15, Av. de France, 1000 Lausanne 7, Switzerland. simone.eperon@fa2.ch
authors.forename: Simone
authors.initials: S
authors.lastname: Eperon
authors.forename: Marta
authors.initials: M
authors.lastname: Rodriguez-Aller
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Balaskas
authors.forename: Robert
authors.initials: R
authors.lastname: Gurny
authors.forename: Yan
authors.initials: Y
authors.lastname: Guex-Crosier
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000737:chemistry; D002387:Cataract Extraction / Q000009:adverse effects*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry; D004338:Drug Combinations; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D019344:Lactic Acid / Q000737:chemistry; D019654:Lens Implantation, Intraocular / Q000379:methods*; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011817:Rabbits; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000627:therapeutic use; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000893:Anti-Inflammatory Agents; D001672:Biocompatible Materials; D004337:Drug Carriers; D004338:Drug Combinations; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D016572:Cyclosporine; D014222:Triamcinolone Acetonide